HIV in the Time of COVID-19: The Case for Investment
As the world continues to grapple with COVID-19, we can’t lose sight of another health crisis: the ongoing HIV epidemic. In this Gilead-created policy paper, read about the critical role that continued investment in HIV can play in supporting public health and achieving our shared goal of ending the epidemic by 2030.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.